https://apnews.com/608d4bb9d76bb1077dec5409a7e2459e

WASHINGTON (AP) — The pharmaceutical giant that makes a promising coronavirus drug has registered it as a rare disease treatment with U.S. regulators, a status that can potentially be worth millions in tax breaks and competition-free sales.

What that specialty status will actually mean for the marketing or profitability of the Gilead Science's experimental drug remdesivir isn't clear. The drugmaker did not immediately respond Tuesday to requests for comment.